Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Wake Forest University Health Sciences
Modality
Small molecule
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Coronary Artery Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dl-Dobutamine (this asset) | Wake Forest University Health Sciences | Early P1 | C · 39 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Ezetimibe | Canadian Collaborative Research Network | P4 | BBB |
| Simvastatin | University of Washington | P4 | BBB |
| Rivaroxaban | Sheffield Teaching Hospitals NHS Foundation Trust | P4 | BBB |
| Ranolazine | OBS Pakistan | P4 | BBB |
| Pitavastatin | Yokohama City University Medical Center | P4 | BBB |
| Clopidogrel | Beijing Tiantan Hospital | P4 | BB |
| Cilostazol | Kyunghee University Medical Center | P4 | BB |
+40 more in the Coronary Artery Disorder cohort
Other indications for Dl-Dobutamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infectious Disease With Sepsis | — | P2 | CCC · 53 |
| Traumatic Brain Injury | — | P2 | CCC · 53 |
| Vascular Insufficiency Disorder | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dl-Dobutamine in Coronary Artery Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dl-dobutamine-coronary-artery-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →